A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma. Issue 11 (2nd November 2015)

• Record Type: Journal Article
• Authors: Wang, Liang; Xia, Zhong-jun; Lu, Yue; Wang, Qiao-xuan; Niu, Shao-qing; Huang, Hui-qiang; Zhang, Yu-jing
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 11(2015:Nov.)
• Page Start: 3038
• Page End: 3044
• Publication Date: 2015-11-02
• Subjects: Anemia -- hemoglobin -- international prognostic index -- extranodal NK/T cell lymphoma -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1026817
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract : In this study, we investigated the prognostic role of pretreatment hemoglobin level in 321 patients with stage I/II extranodal natural killer (NK/T cell lymphoma (ENKTL). Patients with pretreatment hemoglobin level < 120 g/L had significantly inferior progression-free survival (PFS) and overall survival (OS) than those with hemoglobin level ≥ 120 g/L ( p < 0.05). In a multivariate Cox regression model, age, Eastern Cooperative Oncology Group (performance status), lactate dehydrogenase level, Ann Arbor stage and pretreatment hemoglobin level were all independent prognostic factors for PFS and OS ( p < 0.05). Using these five parameters, a modified international prognostic index (mIPI) model was constructed. This mIPI could categorize three groups with significantly different PFS and OS (both p < 0.0001) in both the training set and the validation set. In conclusion, this study confirmed the prognostic role of pretreatment hemoglobin level in ENKTL, and a newly modified IPI including pretreatment hemoglobin level could be used to further optimize treatments for patients with stage I/II ENKTL, especially in the era of asparaginase.